Complement activation by recombinant adenoviruses

Gene Therapy

Volumn 8, Issue 23, 2001, Pages 1794-1800

  Cichon, G ^a   Boeckh Herwig, S ^a   Schmidt, H H ^a   Wehnes, E ^b   Muller T ^a   Pring Akerblom, P ^c   Burger, R ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Adenoviruses; Complement activation; Neutralizing antibodies

Indexed keywords

ADENOVIRUS VECTOR; CITRIC ACID; COMPLEMENT COMPONENT C3A; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADENOVIRUS; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD LEVEL; CALCULATION; CLINICAL PROTOCOL; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DOSE RESPONSE; GENE THERAPY; HUMAN; HUMAN CELL; INFLAMMATION; NORMAL HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION; VIRUS PARTICLE; VIRUS RECOMBINANT; WILD TYPE;

ADENOVIRIDAE; ANTIBODIES, VIRAL; COMPLEMENT ACTIVATION; COMPLEMENT C3A; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GENE THERAPY; GENETIC VECTORS; HUMANS; RECOMBINATION, GENETIC;

ADENOVIRIDAE;

EID: 0035702887     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301611     Document Type: Article

References (31)

1. Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD)
2. The classical complement pathway: Activation and regulation of the first complement component
3. Immune responses to adenovirus and adenoassociated virus in humans
4. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: Implication for gene therapy with adenovirus vectors
5. Cytokines and fever
6. Complement, cytokines, and adhesion molecule expression in inflammatory reactions
7. In vitro and in vivo dependency of chemokine generation on C5a and TNF-alpha
8. The role of complement in inflammation and phagocytosis
9. Anaphylatoxin C3a peptide contracts human pulmonary vasculature
10. Complement activation and lung permeability during cardiopulmonary bypass
11. Human platelet activation by C3a and C3a des-arg
12. Complement activation in injured patients occurs immediately and is dependent on the severity of the trauma
13. Inflammatory mediators in relation to the development of multiple organ failure in patients after severe blunt trauma
14. Complement activation and clearance in acute illness and injury: Evidence for C5a as a cell-directed mediator of the adult respiratory distress syndrome in man
15. The inflammatory basis of trauma/shock-associated multiple organ failure
16. Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome
17. Intravenous administration of recombinant adenoviruses causes thrombocytopenia anemia and erythroblastosis in rabbits
18. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours
19. White blood cell counts and plasma C3a have synergistic predictive value in patients at risk for acute respiratory distress syndrome
20. Prostaglandin and complement interaction in clinical acute respiratory failure
21. The effects of methylprednisolone on complement, immunoglobulins and pulmonary neutrophil sequestration during cardiopulmonary bypass
22. Modifying risk for extracorporeal circulation: Trial of four anti-inflammatory strategies
23. Combined antithrombin III and C1-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coli endotoxin
24. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock
25. C1 inhibitor in anti-inflammatory therapy: From animal experiment to clinical application
26. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5
27. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy
28. The C terminus of the anaphylatoxin C3a generated upon complement activation represents a neoantigenic determinant with diagnostic potential
29. Quantitation of the anaphylatoxin C3a in the presence of C3 by a novel sandwich ELISA using monoclonal antibody to a C3a neoepitope